KNOWLEDGE BANK

Interviews

Exploring New Molecular Targets for Anti-cancer Therapy

Clinical Professor, Department of Medicine, University of British Columbia
Amil Shah is Clinical Professor of Medicine at the University of British Columbia His practice focusses on gastrointestinal and lung cancers Among his administrativeacademic roles he chaired the Gastrointestinal Tumour Group at BC Cancer and served as Associate Dean of the VancouverFraser Medical Program at UBC His research interest is the molecular pathogenesis of cancer

Articles

Kinase Inhibitors as Antiviral Agents

The emergence of virus infections is a serious issue and the development of broadly acting antivirals has heightened concern for future viral epidemics The majority of these drugs operate directly on the proteins encoded by the individual viral genome However they have the following disadvantages i limited treatment coverage which does not address

Research Insights

How Growers Make Decisions Impacts Plant Disease Control

While the spread of plant disease depends strongly on biological factors driving transmission it also has a human dimension Disease control depends on decisions made by individual growers who are in turn influenced by a broad range of factors Despite this human behaviour has rarely been included in plant epidemic models

Case Studies

Cyclodextrins as Active Pharmaceutical Ingredients for The Treatment Of GM1-Gangliosidosis: A Feasibility Case Study

Abstract GMgangliosidosis is a rare lysosomal storage disorder characterized clinically by a wide range of variable neurovisceral ophthalmological and dysmorphic features Without enough functional galactosidase GMgangliosides cannot be degraded in lysosomes and accumulate to toxic levels in many tissues and organs particularly in the brain In s

Techno Trends

Novartis Promacta® Approved as First-Line Treatment for Severe Aplastic Anemia(SAA)

Novartis Promacta is approved as the firstline treatment for adults and pediatric patients two years and older with Severe Aplastic Anemia SAA in combination with standard immunosuppressive therapy IST Promacta is an oral thrombopoietin receptor agonist TPORA that is already approved for SAA for patients who have had an insufficient response to IST It can also b...

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Generative AI and the New Era of Personalized Medicine

Uddalak Das

Uddalak Das, PhD scholar at IISc Bengaluru, specializes in drug discovery and cancer immunotherapeutics. With 20+ publications, a patent, and collaborations with institutes like NCBS, JNU, and inStem, he advances green healthcare solutions. He is a member of AACR and EACR among others and has received multiple national fellowships and research grants.

2

Futuristic Application of Human-On-A-Chip Technology

Joseph Xavier

Joseph Xavier is currently pursuing his PhD in the Division of Toxicology,SCTIMST, Trivandrum, Kerala. He is currently working on the development of multi-organ-on-a-chip for disease modelling and toxicity assessments. His work also focuses on elucidating the cellular mechanism of toxicity of nanomaterials.

 

Akhil Venugopal

Akhil Venugopal is currently working as a Junior Research Fellow in the Division of Toxicology, SCTIMST, Trivandrum. He obtained his Integrated BS-MS in Chemistry from Indian Institute of Science Education and Research (IISER), Mohali. His research work is focused on the fabrication of multi-organ micro physiological devices for pre-clinical studies.

 

Arathi Ashok

Arathi Ashok obtained her Masters in Microbiology from Amrita Vishwa Vidyapeetham, Kerala. She is currently working as a Junior Research Fellow in the Division of Toxicology, SCTIMST, Trivandrum. Her research work lies in the development of organ-on-a chip devices for toxicity assessment.

 

PV. Mohanan

PV. Mohanan, FNASc, FRSB, Scientist-G and Head of Division of Toxicology and Associate Dean (PhD program) in Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Govt. of India. He has more than 33 years of research experience in Toxicology. He is a Certified Biological Safety Specialist and has authored 233 publications and edited 6 books. He is also a Visiting Professor and Visiting Researcher at Toyo University, Japan.

 

3

The Value in Decolonising Drug Discovery

Jesse Grey Eagle

Jesse Grey Eagle (Oglala Lakota) is the founder of Indigenous Futures OS and a governance designer for Tribal nations. He works at the nexus of ethical data, AI sovereignty, and long-view institutional systems, advocating for partnership architectures that move beyond extraction.

Dr. Sabah Ul-Hasan

Sabah Ul-Hasan is a Ph.D. scientist with over 15 years of practice in the life sciences. An Indian-Pakistani American based in Albuquerque (New Mexico), Dr. Ul-Hasan centers on ethical data practices that bridge science with community-based knowledge systems.

4

Harnessing Artificial Intelligence

Anita-Ioana Visan

Anita-Ioana Visan, a Scientific Researcher 2nd degree, at the Laser-Surface-Plasma Interactions (LSPI) Laboratory, Lasers Department, National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, is an expert in nanopowders synthesis and characterisation, as well as thin coatings of calcium phosphates, biopolymers, flavonoids, antibiotics, and antimicrobial peptides synthesized by Pulsed Laser Deposition, Matrix Assisted Pulsed Laser Evaporation, and Combinatorial-MAPLE. Moreover, she has a profound knowledge of thin films characterisation methods, including UV-Vis, FTIR, XRD, SEM, AFM, fluorescence microscopy, electrochemical, magnetic induction, biodegradation, and antimicrobial tests. With her current research focusing on the cutting-edge fields of artificial neural networks, drug repurposing, and pharmaceutical AI, she is paving the way for innovative solutions that have the potential to revolutionise the field of medicine. If you would like to contact her, please use the following email address: anita.visan@inflpr.ro. Furthermore, you can find her professional profile at https://orcid.org/0000-0003-0539-4160.

 

Irina Negut

Irina Negut is a Scientific Researcher 2nd degree, at the National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, Romania. She has important experience in fabricating and investigating the characteristics and (bio) functionality of nano-sized/-structured materials (including composite and hybrid particles, thin films and laser-processed coatings). Her research activity includes coating synthesis by laser-assisted techniques. She is also highly experienced in evaluating the compositional and microstructural aspects of nanomaterials and coatings, but also in assessing their optical, thermal, electrical, and electrochemical properties. If you would like to contact her, please use the following email address: negut.irina@inflpr.ro. Her professional profile can be found at https://orcid.org/0000-0003-4038-7548.

 

5

Smart Polymeric Nanocomposites for Cancer Therapeutics

Saurabh Shivalkar

Saurabh Shivalkar is a research fellow at Department of Applied Sciences, IIIT Allahabad, India. He did his M. Tech (Biomedical Engineering) from IIIT Allahabad. He has recently filed patent and published multiple papers in the allied areas of biomedical engineering and nanobiotechnology.

 

Sneha Ranjan

Sneha Ranjan is currently pursuing M.Sc. (Biotechnology) at Department of Biotechnology of Babasaheb Bhimrao Ambedkar University, Lucknow. She has worked on projects such as purification and characterisation of enzyme, production of recombinant proteins for diagnostics and therapeutics. She is currently working on polymeric nanocomposites for cancer therapeutics.

 

press releasesRead more...

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays

Monod Bio a Seattlebased AIenabled protein design company and SignalChem Biotech Inc a whollyowned subsidiary of Sino Biological Inc SZSE today announced a nonexclusive licensing agreement

Lotus Pharmaceutical Announces Favorable U.S. Appeals Court Ruling on Norwich’s Application for Generic Rifaximin

Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange a leading global pharmaceutical company today announced that Norwich Pharmaceuticals Inc Norwich a wholly owned subsidiary of Alvogen

SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’ Paves the Way to Launch its Second Innovative Drug Directly in the U.S.

SK Biopharmaceuticals Co Ltd wwwskbpcom CEO Donghoon Lee held a press conference on August th and announced that it has entered into an agreement to inlicense opakalim an investigational

DKSH Performance Materials Expands its Pharma Business Through the Acquisition of P.R. Chemicals in Thailand

DKSH has signed an agreement to acquire PR Chemicals Company Limited PR Chemicals a Thai distributor specialized in Active Pharmaceutical Ingredients APIs

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

Celltrion KRX today announced the launch of the mg strength of Omlyclo omalizumab a treatment for chronic spontaneous urticaria and allergic asthma in Europe With the addition

ASTRI and Saint Francis University Sign MoU to Advance AI-Enabled Biomaterials and Digital Health Innovation

The Hong Kong Applied Science and Technology Research Institute ASTRI and Saint Francis University SFU have signed a Memorandum of Understanding MoU to establish a strategic partnership focused on advancing

EventsRead more...

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

Jazz Pharmaceuticals Announces Approval of Ziihera Regimens for Advanced HER2-Positive Gastroesophageal Cancer

Jazz Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved two Ziihera zanidatamabhriibased treatment regimens for the firstline treatment of adults with unresectable

BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients

BioCryst Pharmaceuticals has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORLADEYO berotralstat for the prevention of hereditary angioedema HAE attacks in children aged to under years

Takeda Receives Approval for ORZEYFUL (oveporexton) to Treat Narcolepsy Type 1

Takeda has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORZEYFUL oveporexton for the treatment of narcolepsy type NT a form of narcolepsy associated with cataplexy in adults

Johnson & Johnson’s IMAAVY Approved in the US as First Treatment for Warm Autoimmune Haemolytic Anaemia

Johnson Johnson has announced that the US Food and Drug Administration FDA has approved IMAAVY nipocalimabaahu for the treatment of warm autoimmune haemolytic anaemia wAIHA in adults and children aged years and older who are currently or previously treated with corticosteroids

Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan

Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange has received marketing approval in Japan for its generic pomalidomide capsules in mg mg mg and mg strengths following a review

Ultragenyx Receives U.S. FDA Approval for GENGLYCOS Gene Therapy for Glycogen Storage Disease Type Ia

Ultragenyx Pharmaceutical Inc NASDAQ RARE has received accelerated approval from the US Food and Drug Administration FDA for GENGLYCOS pariglasgene brecaparvovecopnr also known as DTX for adults and children aged eight years and older with glycogen storage disease type Ia GSDIa